1. Home
  2. KOSS vs CNTB Comparison

KOSS vs CNTB Comparison

Compare KOSS & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Koss Corporation

KOSS

Koss Corporation

HOLD

Current Price

$3.60

Market Cap

39.3M

ML Signal

HOLD

Logo Connect Biopharma Holdings Limited

CNTB

Connect Biopharma Holdings Limited

HOLD

Current Price

$2.67

Market Cap

128.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOSS
CNTB
Founded
1953
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.3M
128.6M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
KOSS
CNTB
Price
$3.60
$2.67
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
18.6K
239.9K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
10.00
75.22
EPS
N/A
N/A
Revenue
$12,624,170.00
$26,033,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$17,706.72
P/E Ratio
N/A
N/A
Revenue Growth
2.93
N/A
52 Week Low
$3.50
$0.51
52 Week High
$8.59
$3.82

Technical Indicators

Market Signals
Indicator
KOSS
CNTB
Relative Strength Index (RSI) 41.06 45.46
Support Level N/A $2.16
Resistance Level $4.82 $2.78
Average True Range (ATR) 0.21 0.35
MACD -0.02 -0.00
Stochastic Oscillator 30.16 7.87

Price Performance

Historical Comparison
KOSS
CNTB

About KOSS Koss Corporation

Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.

About CNTB Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

Share on Social Networks: